Experience With Antibody-Based Therapies for COVID-19 for Immunocompromised Patients
- PMID: 40898821
- DOI: 10.1111/tid.70098
Experience With Antibody-Based Therapies for COVID-19 for Immunocompromised Patients
References
-
- S. Shoham, C. Batista, Y. Ben Amor, et al., “Vaccines and Therapeutics for Immunocompromised Patients With COVID‐19,” eClinicalMedicine 59 (2023): 101965, https://doi.org/10.1016/j.eclinm.2023.101965.
-
- P. Chen, A. Nirula, B. Heller, et al., “SARS‐CoV‐2 Neutralizing Antibody LY‐CoV555 in Outpatients With Covid‐19,” New England Journal of Medicine 384, no. 3 (2021): 229–237, https://doi.org/10.1056/NEJMoa2029849.
-
- "Bamlanivimab EUA Letter of Authorization 03022021," US Food & Drug Administration, accessed March 2, 2021, https://www.fda.gov/media/143602/download.
-
- "Convalescent Plasma EUA Letter of Authorization," US Food & Drug Administration, published December 28, 2021, https://www.fda.gov/media/141477/download.
-
- "Paxlovid Letter of Authorization," US Food & Drug Administration, published March 13, 2024, https://www.fda.gov/media/155049/download.
Publication types
LinkOut - more resources
Full Text Sources